Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Zhang, Anli ^a   Xue, Hua ^a   Ling, Xiaoguang ^a   Gao, Yi ^a   Yang, Feng ^a   Cheng, Liansheng ^b   Liu, Jing ^b   Wu, Qiang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHA21 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; NITROBLUE TETRAZOLIUM; PROTEIN BAX; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIBODY; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY ENGINEERING; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; XENOGRAFT; ANIMAL; DRUG EFFECT; DRUG SCREENING; FEMALE; IMMUNOLOGY; METABOLISM; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949434190     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-23     Document Type: Article

References (37)

1. Cancer statistics. A Jemal R Siegel E Ward, et al. Cancer Journal for Clinicians 2008 58 71 96 10.3322/CA.2007.0010
2. Screening and detection of ovarian cancer. G Breedlove C Busenhart, Journal of Midwifery & Women's Health 2005 50 51 54 (Pubitemid 40103890)
3. The biology of ovarian cancer: new opportunities for translation. RC Bast B Hennessy GB Mills, Nature Reviews Cancer 2009 9 415 428 10.1038/nrc2644 19461667
4. Receptors for epidermal growth factor and other polypeptide mitogens. G Carpenter, Annu Rev Biochem 1987 56 881 914 10.1146/annurev.bi.56.070187.004313 3039909
5. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. L Coussens TL Yang-Feng YC Liao, et al. Science 1985 230 1132 1139 10.1126/science.2999974 2999974
6. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. NC Popescu CR King MH Kraus, Genomics 1989 4 362 366 10.1016/0888-7543(89)90343-1 2565881
7. Untangling the ErbB signalling network. Y Yarden MX Sliwkowski, Nat Rev Mol Cell Biol 2001 2 127 137 10.1038/35052073 11252954 (Pubitemid 33674041)
8. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. DJ Slamon W Godolphin LA Jones, Science 1989 244 707 712 10.1126/science.2470152 2470152
9. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. E Verri P Guglielmini M Puntoni, Oncology 2005 68 154 161 10.1159/000086958 16020953 (Pubitemid 41158970)
10. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. JD Cheng PT Rieger M von Mehren, Semin Oncol Nurs 2000 16 2 12 10.1053/sonu.2000.19775 11151455
11. What Can We Learn from Herceptin Trials in Metastatic Breast Cancer? Richard Bell, Oncology 2002 63 39 46 10.1159/000066200 12422054
12. Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2. Mauricio Cuello A Seth Ettenberg S Amy, et al. Cancer Res 2001 61 4892 900 11406568 (Pubitemid 32691907)
13. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. HS Cho K Mason KX Ramyar, et al. Nature 2003 421 756 760 10.1038/nature01392 12610629 (Pubitemid 36227628)
14. HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. M Fujimura N Katsumata H Tsuda, et al. Jpn J Cancer Res 2002 93 1250 1257 12460467 (Pubitemid 36032989)
15. Her2-positive breast cancer: herceptin and beyond. W Dean-Colomb FJ Esteva, Eur J Cancer 2008 44 2806 2812 10.1016/j.ejca.2008.09.013 19022660
16. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). LS Cheng AP Liu JH Yang, Cell Res 2003 13 35 48 10.1038/sj.cr.7290149 12643348
17. Purification and characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system. Jing Wang Yu Shi Yanqi Liu, Protein expression and purification 2005 41 68 76 10.1016/j.pep.2004.11.007 15802223 (Pubitemid 40406365)
18. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. S Hu Z Zhu L Li, et al. Proteins 2008 70 938 949 10.1002/prot.21551 17847085
19. neu/c-erbB-2 by surface epitope masking (SEM). C Wang Y Li P Li, J Chin Immunol 2000 16 539 541
20. Investigation on the anti-cancer activities of anti-p185 monoclonal antibodies in vitro. LI Ping LI Yun Wang Chen, Chin Immunol 2002 18 33 35
21. Differences in radiosensitivity between three HER2 overexpressing cell lines. AC Steffen L Göstring V Tolmachev, et al. Eur J Nucl Med Mol I 2008 35 1179 1191 10.1007/s00259-007-0713-x
22. Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. L Sujun L Xun L Daxu, et al. International Immunopharmacology 2006 6 1387 1393 10.1016/j.intimp.2006.02.002 16846832
23. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. JG Jackson P St Clair MX Sliwkowski, et al. Cancer Res 2004 64 2601 2609 10.1158/0008-5472.CAN-03-3106 15059917
24. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. CL Vogel MA Cobleigh D Tripathy, et al. J Clin Oncol 2002 18 719 726 10.1200/JCO.20.3.719 (Pubitemid 34111379)
25. Cardiac toxicity of ErbB2-targeted therapies: what do we know? EA Perez, Clin Breast Cancer 2008 8 114 120 10.3816/CBC.2008.s.007
26. Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography. K Hattori Y Nishi S Nakamura, Rinsho Byori 2007 55 120 125 17390714
27. Pulmonary complications of novel antineoplastic agents for solid tumors. B Vahid PE Marik, Chest 2008 133 528 538 10.1378/chest.07-0851 18252919
28. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. DJ Slamon B Leyland-Jones, et al. N Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
29. Trastuzumab: mechanisms of resistance and therapeutic opportunities. A Calabrich S Fernandes Gdos A Katz, Oncology (Williston Park) 2008 22 1250 1258 18980023
30. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. MH Chen, Curr Cardiol Rep 2009 11 167 174 10.1007/s11886-009- 0025-9 19379636
31. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. JN Wang JN Feng M Yua, Mol Immu nol 2004 40 963 969 10.1016/j.molimm.2003.09.012 (Pubitemid 38077040)
32. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. G Tortora G di Isernia C Sandomenico, et al. Cancer Res 1997 57 5107 5111 9371510 (Pubitemid 27498127)
33. Apoptosis. MC Cummings CM Winterford NL Walker, Am J Surg Pathol 1997 21 88 101 10.1097/00000478-199701000-00010 8990145 (Pubitemid 127747155)
34. Up-regulation of bax and down-regulation of bcl-2 is associated with kainate-induced apoptosis in mouse brain. F Gillardon H Wickert M Zimmermann, Neurosci Lett 1995 192 85 88 10.1016/0304-3940(95)11619-8 7675327
35. The bcl-2 protein family: arbiters of cell surival. JM Adams S Cory, Science 1998 281 1322 1326 10.1126/science.281.5381.1322 9735050 (Pubitemid 28406819)
36. Overexpression of HER2 Modulates Bcl-2, Bcl-XL, and Tamoxifen-induced Apoptosis in Human MCF-7 Breast Cancer Cells. K Rakesh M Mahitosh L Allan, et al. Clin Cancer Res 1996 2 1215 1219 9816290 (Pubitemid 26238454)
37. Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. L Zheng X Weiya F BingLiang, et al. Cancer lett 2001 174 151 158 10.1016/S0304-3835(01)00700-5 11689290